Obesity is a complex, chronic disease that has reached epidemic proportions in the United States. Obesity is now linked with numerous health conditions, including many oncologic diagnoses. Its association with prostate cancer, the most prevalent cancer in men, has also been investigated, with studies suggesting a direct relationship between increasing obesity and prostate cancer mortality. Outcomes data for specific interventions in obese patients with prostate cancer have only recently begun to emerge. Surgery, while feasible even in the very obese, may result in less than optimal cancer control rates. Brachytherapy data are emerging, and are promising. No outcomes data are available for the use of external-beam radiation in obese patients. Long-term data for external-beam radiation, as well as for surgery and brachytherapy, are required to determine the most appropriate treatment for obese patients with prostate cancer. These data, coupled with a more thorough understanding of the biochemical relationship between obesity and prostate cancer, will be necessary to make optimal management decisions for obese patients with prostate cancer in the future.
Obesity has increased to epidemic proportions in the United States. The percentage of obese adults has swelled from 13.3% of the adult population in the early 1960s to 31.1% in 1999 through 2002. The potential causes for this increase have been debated, as obesity is a complex, multifaceted, chronic disease mediated by genetics, the psychosocial environment, and physiologic variables. The causes notwithstanding, the detrimental health effects of this demographic shift are becoming clear.
Obesity is a known risk factor for numerous health conditions, including cataracts, coronary heart disease, diabetes, erectile dysfunction, gastro-esophageal reflux disease (GERD), hypercholesterolemia, hypertension, osteoarthritis, and respiratory compromise, among others. Moreover, while some analyses suggest that there is no such association, many studies have linked obesity status with numerous oncologic diagnoses such as uterine, breast, gallbladder, and colon cancer.[4,5] In addition, several studies have investigated the relationship between obesity and prostate cancer with respect to epidemiology and outcome, often with seemingly conflicting results.
Body Mass Index
In such studies, the most frequently utilized method of assessing obesity is the calculation of body mass index (BMI), in which a person's weight in kilograms is divided by the person's height in square meters. A BMI < 25 kg/m2 is considered normal, 25 to 29.9 kg/m2 is considered overweight, while BMI ≥ 30 kg/m2 is considered obese. This latter group is further divided into grade 1 (30-34.9 kg/m2), grade 2 (35-39.9 kg/m2), and grade 3 (≥ 40 kg/m2).
In the Health Professionals Follow-up Study, which is a prospective cohort study of over 51,000 US male health professionals started in 1986, the risk of developing prostate cancer was found to be decreased in men with a BMI ≥ 30 kg/m2 for men younger than 60 years of age or with a family history of prostate cancer. Among men with no family history of prostate cancer, BMI was not statistically associated with prostate cancer development. Some other epidemiologic studies have supported this inverse relationship of obesity and the development of prostate cancer,[8,9] while some have not.
The association between obesity and the risk of developing prostate cancer may be equivocal; studies are fairly consistent, however, in showing a relationship between increasing BMI levels and prostate cancer mortality. An American Cancer Society (ACS) study of over 400,000 US adults showed that the mortality risk associated with prostate cancer increased with higher BMI levels. Patients with grade 1 obesity had a 20% increase in mortality relative to men with a normal BMI between 18.5 and 24.9 kg/m2. Furthermore, men with grade 2 obesity had a 34% increase in mortality relative to men with a normal BMI. An earlier study by the ACS that followed over 450,000 men also suggested an increase in prostate cancer mortality with higher BMI levels. Surgical series have generally demonstrated higher tumor grades and more advanced disease in obese patients, with higher biochemical failure rates even when surgical margins are clear.
Explaining the Relationship
Several hypotheses have been proposed to explain the complex association between obesity and aggressive prostate cancer. Perhaps the most prevalent explanation, given that prostate cancer is a hormonally dependent malignancy, is that obesity affects the hormonal milieu, which in turn affects the biologic progression of prostate cancer. Decreased serum androgen levels have been shown to occur with obesity[14,15]; prostate cancer that proliferates in low-testosterone environments may be inherently partially androgen-independent, and therefore, a more aggressive form of the disease.[16,17] Other hormones, including estradiol, insulin, leptin, and adiponectin, may also exacerbate prostate cancer in obese patients.
Obese patients have increased levels of estradiol, which, in combination with testosterone, may enhance tumorigenesis relative to testosterone alone.[18,19] Obesity is also related to insulin resistance and elevated levels of insulin and insulin-like growth factor (IGF), the latter of which imparts a stimulatory, proliferative effect on cells. Moreover, elevated IGF-1 levels have been shown to specifically increase the risk of prostate cancer, and have been correlated with advanced-stage disease.[21,22] Leptin, a polypeptide hormone produced by adipocytes, has been demonstrated to promote angiogenesis, as well as the growth of androgen-independent cell lines in-vitro. Leptin serum levels are directly associated with the degree of obesity and have been correlated with larger, higher-grade, and more advanced tumors.[23,24] Adiponectin, another adipocyte-produced polypeptide hormone, has been shown to inhibit angiogenesis, and is indirectly related to obesity. Lower adiponectin levels have been associated with higher-grade and more advanced cancer.[25,26]
In addition to these hormonal alterations, difficulties with prostate cancer detection may partly explain the more aggressive nature of prostate cancer at presentation in obese patients. Obesity may result in lower serum prostate-specific antigen (PSA) levels, resulting in delayed biopsies and, consequently, more advanced disease at diagnosis.[14,15] Alternatively, simply having an elevated BMI may impede cancer detection with prostate biopsy. Presti and colleagues reported that overweight and obese men had a lower cancer detection rate by biopsy compared to men with a normal BMI, even when controlling for PSA levels.
The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Flegal KM: Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 86:599-602, 2005.
2. Moyad MA: Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspectives. Urology 59(4 suppl 1):41-50, 2002.
3. Lee JM, Sesso HD, Paffenbarger RS Jr: A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control 12:187-193, 2001.
4. Jonsson F, Wolk A, Pedersen NL, et al: Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 106:594-599, 2003.
5. Kaaks R, Lukanova A: Effects of weight control and physical activity in cancer prevention: Role of endogenous hormone metabolism. Ann NY Acad Sci 963:268-281, 2002.
6. World Health Organization: Physical status: The use and interpretation of anthropometry. Report of a WHO expert committee. Geneva, World Health Organization. Technical Report Series, no. 854, 1995.
7. Giovannucci E, Rimm EB, Liu Y, et al: Body mass index and risk of prostate cancer in US health professionals. J Natl Cancer Inst 95:1240-1244, 2003.
8. Porter MP, Stanford JL: Obesity and the risk of prostate cancer. Prostate 62:316-321, 2005.
9. Bradbury BD, Wilk JB, Kaye JA: Obesity and the risk of prostate cancer (United States). Cancer Causes Control 16:637-641, 2005.
10. Habel LA, Van Den Eeden SK, Friedman GD: Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. Prostate 1:43:136-143, 2000.
11. Calle EE, Rodriguez C, Walker K, et al: Overweight, obesity and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348:1625-1638, 2003.
12. Rodriguez C, Patel AV, Calle EE, et al: Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10:345-353, 2001.
13. Freedland SJ, Terris MK, Presti JC Jr, et al: Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 172:520-524, 2004.
14. Barqawi AB, Golden BK, O'Donnell C, et al: Observed effect of age and body mass index on total and complexed PSA: Analysis from a national screening program. Urology 65:708-712, 2005.
15. Baillargeon J, Pollock BH, Kristal AR, et al: The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103:1092-1095, 2005.
16. Massengill JC, Sun L, Moul JW, et al: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169:1670-1675, 2003.
17. Schatzl G, Madersbacher S, Thurridl T, et al: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52-58, 2001.
18. Shirai T, Imaida K, Masui T, et al: Effects of testosterone, dihydrotestosterone and estrogen on 3,2´-dimethyl-4-aminobiphenyl-induced rat prostate carcinogenesis. Int J Cancer 57:224-228, 1994.
19. Bosland MC, Ford H, Horton L: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 16:1311-1317, 1995.
20. Yu H, Rohan T: Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 95:1472-1489, 2000.
21. Shaneyfelt T, Husein R, Bubley G, et al: Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 18:847-853, 2000.
22. Chan JM, Stampfer MJ, Ma J, et al: Insulin-like growth factor I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106, 2002.
23. Saglam K, Aydur E, Yilmaz M, et al: Leptin influences cellular differentiation and progression in prostate cancer. J Urol 169:1308-1311, 2003.
24. Chang S, Hursting SD, Contois JH, et al: Leptin and prostate cancer. Prostate 46:62-67, 2001.
25. Goktas S, Yilmaz MI, Caglar K, et al: Prostate cancer and adiponectin. Urology 65:1168-1172, 2005.
26. Freedland SJ, Sokoll LJ, Platz EA, et al: Association between serum adiponectin and pathological stage and grade among men undergoing radical prostatectomy. J Urol 174(4 pt 1):1266-1270, 2005.
27. Presti JC, Lee U, Brooks JD, et al: Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 171(6 pt 1):2199-2202, 2004.
28. Pasulka PS, Bistrian BR, Benotti PN, et al: The risks of surgery in obese patients. Ann Intern Med 104:540-546, 1986.
29. Edmonds MJ, Crichton TJ, Runciman WB, et al: Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 74:1982-1997, 2004.
30. Boczko J, Melman A: Radical perineal prostatectomy in obese patients. Urology 62:467-469, 2003.
31. Dahm P, Yang BK, Salmen CR, et al: Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. J Urol 174:181-184, 2005.
32. Brown JA, Rodin DM, Lee B, et al: Laparoscopic radical prostatectomy and body mass index: An assessment of 151 sequential cases. J Urol 173:442-445, 2005.
33. Ahlering TE, Eichel L, Edwards R, et al: Impact of obesity on clinical outcomes in robotic prostatectomy. Urology 65: 740-744, 2005.
34. Bhayani SB, Pavlovich CP, Strup SE, et al: Laparoscopic radical prostatectomy: A multi-institutional study of conversion to open surgery. Urology 63:99-102, 2004.
35. Amling CL, Riffenburgh RH, Sun L, et al: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:349-345, 2004.
36. Freedland SJ, Aronson WJ, Kane CJ, et al: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the shared equal access regional cancer hospital database study group. J Clin Oncol 22:446-453, 2004.
37. Mallah KN, DiBlasion CJ, Rhee AC, et al: Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer 103:2030-2034, 2005.
38. Bassett WW, Cooperberg MR, Sadetsky N, et al: Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology 66:1060-1065, 2005.
39. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005.
40. Swanson GP, Thompson IM, Tangen C, et al: Phase III randomized study of adjuvant radiation therapy vs observation in patients with pathologic T3 prostate cancer (SWOG 8794) (abstract 1). Int J Radiat Oncol Biol Phys 63:S1, 2005.
41. Kupelian PA, Potters L, Khuntia D, et al: Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25-33, 2004.
42. Luchka K, Shalev S: Pelvic irradiation of the obese patient: A treatment strategy involving megavoltage simulation and intratreatment setup corrections. Med Phys 23:1897-1902, 1996.
43. Schallenkamp JM, Herman MG, Kruse JJ, et al: Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys 63:800-811, 2005.
44. Millender LE, Aubin M, Pouliot J, et al: Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59:6-10, 2004.
45. Rockhill J, Wallner K, Hoffman C, et al: Prostate brachytherapy in obese patients. Brachytherapy 1:54-60, 2002.
46. Waller K, Blasko J, Dattoli M: Prostate Brachytherapy Made Complicated, 2nd ed. Seattle, SmartMedicine Press, 2001.
47. Merrick GS, Butler WM, Wallner K, et al: Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 60:104-108, 2002.
48. Merrick GS, Butler WM, Wallner KE, et al: Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 65:95-100, 2005.